The global insulin market is projected to grow from US$ 18.5 billion in 2021 to US$ 30 billion by the end of 2031, with a CAGR of 4.3% from 2022 to 2031. The growth is driven by several factors, ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

The FTC filed a lawsuit in September, accusing the three major PBMs of anticompetitive rebating practices related to insulin.